Curcumin As An Adjunct Therapy During Chemotherapy: Good Idea Or Bad?

Introduction

Curcumin, a biologically active polyphenol derived from turmeric, has been used for centuries in Asian medicine for its therapeutic benefits. Known for its strong antioxidant, anti-inflammatory, and antimicrobial properties, curcumin has been extensively studied for its potential role in the prevention and management of various diseases, including cancer. Traditionally valued in naturopathic medicine for controlling inflammation associated with chronic conditions, interest has recently expanded toward Curcumin as an Adjunct Therapy during chemotherapy. Emerging research suggests it may support conventional cancer treatments, although findings remain mixed. This article reviews current evidence examining curcumin’s supportive potential alongside chemotherapy, while also addressing conflicting research outcomes.

Mechanism of Action

Curcumin’s potential as a therapeutic agent in chemotherapy lies in its multifaceted mechanisms of action. It is an anti-proliferative agent that induces apoptosis (programmed cell death) in a variety of cancer cell lines, including breast, colorectal, pancreatic, and prostate cancer [2]. Curcumin also interferes with the inflammatory pathways that are often upregulated in cancer [3]. Moreover, it has been shown to inhibit angiogenesis (formation of new blood vessels) and metastasis (spread of cancer) [4].

Curcumin as a Chemotherapeutic Adjuvant: Supportive Studies

Many studies support the use of curcumin as an adjuvant during chemotherapy.

A study by Bayet-Robert et al. [5] on 14 metastatic breast cancer patients found that a combination of curcumin and docetaxel, a chemotherapy drug, reduced the size of the tumor and the levels of circulating cancer markers. There was also a decrease in adverse events.

In another study involving 40 colorectal cancer patients, James et al. [6] discovered that a combination of curcumin and FOLFOX chemotherapy (5-fluorouracil, leucovorin, and oxaliplatin) improved the response rate and overall survival compared to FOLFOX chemotherapy alone.

Preclinical research has shown that curcumin can potentiate the effects of chemotherapeutic agents and reduce their side effects. Bayet-Robert et al. [7] showed that curcumin enhances the efficacy of cisplatin in ovarian cancer cells and reduces nephrotoxicity, a common side effect of this drug.

Curcumin has also been shown to overcome drug resistance, a significant challenge in cancer chemotherapy. A study by Lin et al. [8] demonstrated that curcumin could resensitize drug-resistant pancreatic cancer cells to gemcitabine, a chemotherapeutic agent.

Conflicting Studies

While a considerable amount of research supports the use of curcumin as an adjuvant during chemotherapy, some studies suggest otherwise.

A study by Kanai et al. [9] in patients with pancreatic cancer showed no significant improvement in overall survival or progression-free survival when curcumin was added to gemcitabine treatment. The authors suggested that the poor absorption of curcumin might have contributed to the lack of effect.

Another study by Epelbaum et al. [10] involving lung cancer patients found no significant difference in survival rates between patients receiving curcumin and chemotherapy and those receiving chemotherapy alone. They proposed that the high dose of curcumin used might have interfered with the chemotherapeutic agent’s effectiveness.

Additionally, curcumin has been found to interact with certain drugs, potentially reducing their efficacy. Steward et al. [11] found that curcumin could reduce the bioavailability of irinotecan, a chemotherapeutic agent, possibly compromising its anti-cancer effect.

Bioavailability of Curcumin

One of the major challenges in the therapeutic use of curcumin is its poor

bioavailability, largely due to poor absorption, rapid metabolism, and rapid systemic elimination [12]. This can limit its effectiveness as an adjunct to chemotherapy.

However, several strategies are being explored to improve curcumin’s bioavailability. This includes the use of adjuvants like piperine, which inhibits the metabolism of curcumin, thus increasing its bioavailability [13]. Furthermore, the use of nanotechnology in creating nano-curcumin formulations has shown promising results in improving its absorption [14].

Conclusion

The potential benefits of curcumin as an adjunct therapy during chemotherapy are promising, with numerous studies suggesting that it can enhance the efficacy of chemotherapy, reduce side effects, and overcome drug resistance. However, conflicting studies underscore the need for further research to validate these findings and determine the optimal dosing and delivery methods for curcumin. The issue of curcumin’s poor bioavailability is an important factor to consider and is currently being addressed through various strategies. There is no question that further large-scale, randomized controlled trials are needed to definitively establish the role of curcumin in cancer chemotherapy. From a metabolic perspective however, curcumin if prescribed properly, provides too much potential benefit to not be considered -especially in the context of escalating inflammation, as seen in progressive metastatic disease.